A1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III
Por:
Canales, NAG, Marina V.M., Castro J.S., Jiménez A.A., Mendoza-Hernández G., McCarron E.L., Roman M.B., Castro-Romero J.I.
Publicada:
1 ago 2014
Resumen:
The present study aimed to analyze sera proteins in females with cervical intraepithelial neoplasia, grade III (CIN III) and in healthy control females, in order to identify a potential biomarker which detects lesions that have a greater probability of cervical transformation. The present study investigated five sera samples from females who were Human Papilloma Virus (HPV) 16+ and who had been histopathologically diagnosed with CIN III, as well as five sera samples from healthy control females who were HPV-negative. Protein separation was performed using two-dimensional (2D) gel electrophoresis and the proteins were stained with Colloidal Coommassie Blue. Quantitative analysis was performed using ImageMaster 2D Platinum 6.0 software. Peptide sequence identification was performed using a nano-LC ESIMS/MS system. The proteins with the highest Mascot score were validated using western blot analysis in an additional 55 sera samples from the control and CIN III groups. The eight highest score spots that were found to be overexpressed in the CIN III sera group were identified as a-1-B glycoprotein (A1BG), complement component 3 (C3), a pro-apolipoprotein, two apolipoproteins and three haptoglobins. Only A1BG and C3 were validated using western blot analysis, and the bands were compared between the two groups using densitometry analysis. The relative density of the bands of A1BG and C3 was found to be greater in all of the serum samples from the females with CIN III, compared with those of the individuals in the control group. In summary, the present study identified two proteins whose expression was elevated in females with CIN III, suggesting that they could be used as biomarkers for CIN III. However, further investigations are required in order to assess the expression of A1BG and C3 in different pre-malignant lesions.
Filiaciones:
Marina V.M.:
Research Center on Infection Diseases, National Institute of Public Health, Cuernavaca, Morelos 62100, Mexico
Castro J.S.:
Epidemiology and Health Services Research Unit, National Institute of Social Security, Cuernavaca, Morelos 62450, Mexico
Jiménez A.A.:
Epidemiology and Health Services Research Unit, National Institute of Social Security, Cuernavaca, Morelos 62450, Mexico
Mendoza-Hernández G.:
Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Lab Peptides & Prot, Mexico City 04510, DF, Mexico
McCarron E.L.:
Biomedical Cancer Research Unit, Basic Research Subdirection, National Institute of Cancer, Mexico City 14080, Mexico
Roman M.B.:
Research Center on Infection Diseases, National Institute of Public Health, Cuernavaca, Morelos 62100, Mexico
Castro-Romero J.I.:
Research Center on Infection Diseases, National Institute of Public Health, Cuernavaca, Morelos 62100, Mexico
All Open Access, Bronze
|